Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Clever LeavesSpartacus AcquisitionTherapeutics AcquisitionTuscan Holdings Corp. IIImmatics
SymbolNASDAQ:CLVRNASDAQ:TMTSNASDAQ:RACANASDAQ:THCANASDAQ:IMTX
Price Information
Current Price$10.10$9.98$9.95$10.00$12.00
52 Week RangeN/AN/AN/AN/ABuy
MarketRank™
Overall Score1.30.00.30.31.5
Analysis Score0.00.00.00.03.5
Community Score5.00.00.00.03.6
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.71.70.0
Earnings & Valuation Score0.00.00.00.00.6
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/ABuy
Consensus Price TargetN/AN/AN/AN/A$19.60
% Upside from Price TargetN/AN/AN/AN/A63.33% upside
Trade Information
Market Cap$264.08 million$199.60 million$139.71 million$191.52 million$215.64 million
Beta0.18N/AN/A0.12-0.1
Average Volume1,198,74873,550105,769344,603706,299
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
Cashflow$0.11 per shareN/AN/A$0.04 per share$0.16 per share
Price / Cash90.04N/AN/A233.6076.01
Book Value$0.31 per shareN/AN/A$9.10 per share$0.28 per share
Price / BookN/AN/AN/AN/AN/A
Profitability
Net Income$1.81 millionN/AN/A$890,000.00$2.58 million
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E Ratio∞∞∞∞N/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)2.50%N/AN/A0.61%-1,105.30%
Return on Assets (ROA)0.09%N/AN/A0.61%-37.06%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio0.57%N/A24.45%1.45%N/A
Quick Ratio0.57%N/A24.45%1.45%N/A
Ownership Information
Institutional Ownership Percentage77.80%N/A91.97%67.48%N/A
Insider Ownership Percentage20.00%N/AN/AN/AN/A
Miscellaneous
Employees477N/AN/AN/A227
Shares Outstanding26.15 million20.00 million14.04 million19.15 million17.97 million
Next Earnings Date5/7/2021 (Estimated)N/AN/A5/3/2021 (Estimated)6/29/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Immatics (NASDAQ:IMTX) Sees Significant Growth in Short InterestImmatics (NASDAQ:IMTX) Sees Significant Growth in Short Interest
americanbankingnews.com - April 15 at 11:48 AM
Brokerages Anticipate Immatics (NASDAQ:IMTX) Will Announce Quarterly Sales of $9.62 Million Brokerages Anticipate Immatics (NASDAQ:IMTX) Will Announce Quarterly Sales of $9.62 Million
americanbankingnews.com - April 12 at 1:24 AM
Immatics (NASDAQ:IMTX) Receives Consensus Rating of "Buy" from AnalystsImmatics (NASDAQ:IMTX) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - April 11 at 6:06 AM
Immatics (NASDAQ:IMTX) Expected to Post Earnings of -$0.34 Per ShareImmatics (NASDAQ:IMTX) Expected to Post Earnings of -$0.34 Per Share
americanbankingnews.com - April 10 at 10:12 PM
Global Cancers Immunotherapy Drugs Market Updates 2020-2025 in Latest Research Highlighting Current and Future Trends – ROUGH Magazine - ROUGH MagazineGlobal Cancers Immunotherapy Drugs Market Updates 2020-2025 in Latest Research Highlighting Current and Future Trends – ROUGH Magazine - ROUGH Magazine
rough.asia - April 7 at 7:15 PM
Immatics (IMTX) "Buy" Rating Reiterated at Chardan CapitalImmatics' (IMTX) "Buy" Rating Reiterated at Chardan Capital
americanbankingnews.com - April 4 at 12:42 PM
Immatics (NASDAQ:IMTX) versus Arko (NASDAQ:ARKO) Financial AnalysisImmatics (NASDAQ:IMTX) versus Arko (NASDAQ:ARKO) Financial Analysis
americanbankingnews.com - April 4 at 4:20 AM
What Kind Of Investors Own Most Of Immatics N.V. (NASDAQ:IMTX)? - Yahoo FinanceWhat Kind Of Investors Own Most Of Immatics N.V. (NASDAQ:IMTX)? - Yahoo Finance
finance.yahoo.com - April 3 at 11:32 AM
What Kind Of Investors Own Most Of Immatics N.V. (NASDAQ:IMTX)?What Kind Of Investors Own Most Of Immatics N.V. (NASDAQ:IMTX)?
finance.yahoo.com - April 3 at 11:32 AM
SVB Leerink Comments on Immatics FY2022 Earnings (NASDAQ:IMTX)SVB Leerink Comments on Immatics' FY2022 Earnings (NASDAQ:IMTX)
americanbankingnews.com - April 2 at 9:24 AM
Jefferies Financial Group Weighs in on Immatics Q1 2021 Earnings (NASDAQ:IMTX)Jefferies Financial Group Weighs in on Immatics' Q1 2021 Earnings (NASDAQ:IMTX)
americanbankingnews.com - April 2 at 7:56 AM
IMTX Stock Price Increased Over 5% Pre-Market: Why It Happened - Pulse 2.0IMTX Stock Price Increased Over 5% Pre-Market: Why It Happened - Pulse 2.0
pulse2.com - March 30 at 11:13 PM
Form 20-F Immatics NV For: Dec 31 - StreetInsider.comForm 20-F Immatics NV For: Dec 31 - StreetInsider.com
streetinsider.com - March 30 at 11:13 PM
Immatics Announces Full Year 2020 Financial Results and Corporate UpdateImmatics Announces Full Year 2020 Financial Results and Corporate Update
markets.businessinsider.com - March 30 at 1:12 PM
Immatics Announces Full Year 2020 Financial Results and Corporate Update - Yahoo FinanceImmatics Announces Full Year 2020 Financial Results and Corporate Update - Yahoo Finance
finance.yahoo.com - March 30 at 8:12 AM
Immatics Announces Full Year 2020 Financial Results and Corporate UpdateImmatics Announces Full Year 2020 Financial Results and Corporate Update
finance.yahoo.com - March 30 at 8:12 AM
Immatics (NASDAQ:IMTX) Expected to Announce Quarterly Sales of $9.56 MillionImmatics (NASDAQ:IMTX) Expected to Announce Quarterly Sales of $9.56 Million
americanbankingnews.com - March 26 at 9:05 AM
IMTX Stock Price Increased Over 58% Intraday: Why It HappenedIMTX Stock Price Increased Over 58% Intraday: Why It Happened
pulse2.com - March 17 at 7:48 PM
Why Immatics Stock Is Soaring TodayWhy Immatics Stock Is Soaring Today
fool.com - March 17 at 4:34 PM
Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer PatientsImmatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients
markets.businessinsider.com - March 17 at 2:40 PM
IMTX Stock: Why Immatics Shares Are Rocketing Higher TodayIMTX Stock: Why Immatics Shares Are Rocketing Higher Today
feedproxy.google.com - March 17 at 1:22 PM
https://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programshttps://immatics.com/: Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs
finanznachrichten.de - March 17 at 9:40 AM
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy ProgramsImmatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs
finance.yahoo.com - March 17 at 9:40 AM
Immatics: Bursting With Big Pharma PartnershipsImmatics: Bursting With Big Pharma Partnerships
seekingalpha.com - March 15 at 11:22 PM
Is IMTX A Good Stock To Buy Now According To Hedge Funds?Is IMTX A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 18 at 6:58 PM
DateCompanyBrokerageAction
4/4/2021ImmaticsChardan CapitalReiterated Rating
3/23/2021ImmaticsSVB LeerinkBoost Price Target
11/20/2020ImmaticsBank of AmericaInitiated Coverage
9/21/2020ImmaticsThe Goldman Sachs GroupInitiated Coverage
7/24/2020ImmaticsJefferies Financial GroupInitiated Coverage
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.